REported Outcomes in COPD with Trixeo in Real worlD - RECORD

Study identifier:D5980R00051

ClinicalTrials.gov identifier:NCT05213611

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A non-interventional, multi-centre study to investigate the change in clinical and patient-reported outcomes in moderate to severe COPD patients treated with TRIXEO (Budesonide / Glycopyrronium / Formoterol) under real-life conditions

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

148

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 11 Aug 2022
Primary Completion Date: 30 Jul 2024
Study Completion Date: 30 Jul 2024

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria